Create a narrative

Axsome Therapeutics Community

NasdaqGM:AXSM Community

1 Narratives written by author
0 Comments on narratives written by author
48 Fair Values set on narratives written by author

Create a narrative

Axsome Therapeutics

AN

AnalystConsensusTarget

Consensus Narrative from 17 Analysts

R&D Pipeline And NDAs Will Unlock New Approvals

Key Takeaways Ongoing R&D and product launch efforts, including key NDA submissions, may significantly enhance future revenues through new product approvals. Strategic commercial expansion and a digital-centric approach could bolster revenues and earnings growth, with operational efficiencies improving net margins.

US$177.35

FV

36.7% undervalued

57.92%

Revenue growth p.a.

1

0

0

2 days ago